Researchers Discover New Therapy for a Common Childhood Cancer that has Fewer Side Effects

This weekend at the American Society of Clinical Oncology (ASCO) Annual Meeting, Children’s Oncology Group (COG) researchers will present promising findings from an international study that has identified a new therapy for treating rhabdomyosarcoma, a common childhood cancer. The therapy has fewer harsh side effects, meaning it lessens the chance of infections, need for blood…
Continue Reading »

Patient-Derived Xenografts for Individualized Care in Advanced Sarcoma

In line with Dr. Judy Davie's webinar on Patient Derived Xenografts (PDXs), you might also want to read the following article published in the March 2014 issue of Cancer: Patient-Derived Xenografts for Individualized Care in Advanced Sarcoma.  PMID24705963-PDX-for-RMS Background: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few…
Continue Reading »

MSKCC To Open Center for Molecular Oncology

From Dr. Len Wexler To the Memorial Sloan Kettering Community: I am pleased to announce that Memorial Sloan Kettering is today launching an ambitious initiative to improve cancer care and research through genomic analysis. This collaborative effort, involving both researchers and clinicians, will reshape clinical trials and speed the translation of novel molecular discoveries into…
Continue Reading »

Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group.

UPDATED: Dr. Philip Lupo of the Texas Children's Cancer Center of Baylor College of Medicine, sent me a very interesting paper that looks at rhabdomyosarcoma from a different perspective - through the lens of allergies, atopy, and immune-related factors. The report was published by the Children's Oncology Group in the International Journal of Cancer. The…
Continue Reading »

Hyundai Hope on Wheels Funds Rhabdo Research

Hyundai Motor America launched its 16th year in the battle against pediatric cancer and has awarded $86 million in research funding. An article on the website reports that Hyundai has, this year, awarded funds for a clinical trail for rhabdomyosarcoma. "Dr. Leo Mascarenhas of Children's Hospital Los Angeles was awarded funds for a pilot clinical…
Continue Reading »

PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma

Many congratulations to Imran (Aslam) for his publication, PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma, today in the Proceedings of the National Academy of Sciences of the USA. This study was a collaboration of the Tyner, Druker and Keller laboratories - highlighting some key growth factor receptor targets in this disease. This study was funded…
Continue Reading »

Patient-derived xenografts for individualized care in advanced sarcoma

Patient-derived xenografts for individualized care in advanced sarcoma (Article first published online 4 April 2014) AUTHORS: Justin Stebbing MA, FRCP, FRCPath, PhD, Keren Paz PhD, Gary K. Schwartz MD, Leonard H. Wexler MD, Robert Maki MD, PhD, Raphael E. Pollock MD, PhD, Ronnie Morris MD, Richard Cohen MD, Arjun Shankar MD, Glen Blackman MBBS, Victoria…
Continue Reading »

Double-pronged attack could treat common children’s cancer

Shipley - Double-Pronged Attack Double-pronged attack could treat common children's cancer Date: November 1, 2013 Source: Institute of Cancer Research A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new…
Continue Reading »
Skip to toolbar